Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 3, 1999, Pages 351-357

  Sato, K ^a   Tomioka, H ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; NITROGEN; RIFALAZIL;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; MOUSE; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PERITONEUM MACROPHAGE;

EID: 0032998791     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.3.351     Document Type: Article

References (24)

1. Benson, C. A. & Ellner, J. J. (1993). Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clinical Infectious Diseases 17, 7-20.
2. Benson, C. A. (1996). Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Research in Microbiology 147, 16-24.
3. Saito, H., Tomioka, H., Sato, K., Emori, M., Yamane, T., Yamashita, K. et al. (1991). In-vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy 35, 542-7.
4. Inderlied, C. B., Barbara-Bumham, L., Wu, M., Young, L. S. & Bermudez, L. E. M. (1994). Activities of benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy 38, 1838-43.
5. Saito, H., Tomioka, H., Sato, K. & Dekio, S. (1994). In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex. International Journal of Antimicrobial Agents 4, 175-81.
6. Heifets, L. B. (1996). Clarithromycin against Mycobacterium avium complex infections. Tubercle and Lung Disease 77, 19-26.
7. Mor, N., Simon, B. & Heifets, L. (1996). Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrobial Agents and Chemotherapy 40, 1482-5.
8. Tomioka, H., Saito, H., Sato, K., Yamane, T., Yamashita, K., Hosoe, K. et al. (1992). Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy 36, 387-93.
9. Saito, H., Tomioka, H., Sato, K., Kawahara, S., Hidaka, T. & Dekio, S. (1995). Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tubercle and Lung Disease 76, 51-8.
10. Sato, K., Akaki, T. & Tomioka, H. (1998). Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. Journal of Antimicrobial Chemotherapy 41, 77-83.
11. Bermudez, L. E. & Goodman, J. (1996). Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infection and Immunity 64, 1400-6.
12. Mehta, P. K., King, C. H., White, E. H., Murtagh, J. J. & Quinn, F. D. (1996). Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infection and Immunity 64, 2673-9.
13. McDonough, K. A. & Kress, Y. (1995). Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infection and Immunity 63, 4802-11.
14. Wright, E. L., Quenelle, D. C., Suling, W. J. & Barrow, W. W. (1996). Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrobial Agents and Chemotherapy 40, 2206-6.
15. Tomioka, H., Saito, H., Sato, K. & Dawson, D. J. (1993). Comparison of the virulence for mice of Mycobacterium avium and Mycobacterium intracellulare identified by DNA probe test. Microbiology and Immunology 37, 259-64.
16. Suwa, T., Yoshida, H., Fukushima, K. & Nagate, T. (1988). Metabolic fate of TE-031 (A-56268). (I) Comparative pharmacokinetics of TE-031 and erythromycin stearate in rats and mice. Chemotherapy 36, Suppl. 3, 198-204.
17. Yajuko, D. M., Nassos, P. S. & Hadley, W. K. (1987). Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium from patients with acquired immune deficiency syndrome. Antimicrobial Agents and Chemotherapy 31, 1579-84.
18. Akaki, T., Sato, K., Shimizu, T., Sano, C., Kajitani, H., Dekio, S. et al. (1997). Effector molecules in expression of the antimicrobial activity of macrophages against Mycobacterium avium complex: the roles of reactive nitrogen intermediates, reactive oxygen intermediates, and free fatty acids. Journal of Leukocyte Biology 62, 795-804.
19. Tomioka, H., Sato, K., Shimizu, T., Sano, C., Akakai, T., Saito, H. et al. (1997). Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy 41, 357-62.
20. Chan, J. & Kaufmann, S. H. E. (1994). Immune mechanisms of protection. In Tuberculosis. Pathogenesis, Protection, and Control (Bloom, B. R., Ed.), pp. 389-415. ASM Press, Washington DC.
21. Tomioka, H., Sato, K., Sano, C., Akaki, T., Shimizu, T., Kajitani, H. et al. (1997). Effector molecules of the host defence mechanism against Mycobacterium avium complex: the evidence showing that reactive oxygen intermediates, reactive nitrogen intermediates, and free fatty acids each alone are not decisive in expression of macrophage antimicrobial activity against the parasites. Clinical and Experimental Immunology 109, 248-54.
22. Hiemstra, P. S., Eisenhauer, P. B., Harwig, S. S. L., van den Barselaar, M. T., van Furth, R. & Lehrer, R. I. (1993). Antimicrobial proteins of murine macrophages. Infection and Immunity 61, 3038-46.
23. Frehel, C., Offredo, C. & De Chastellier, C. (1997). The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. Infection and Immunity 65, 2792-802.
24. Bermudez, L. E., Parker, A. & Goodman, J. R. (1997). Growth within macrophages increases the efficacy of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway. Infection and Immunity 65, 1916-25.